Since it is approved in 2003 by the State FDA of China, many RCTs of rAd-p53 have been performed for treating malignant tumors, including lung cancer, liver cancer, malignant glioma and ovarian carcinoma. This evidence concerns the gene TP53 and ovarian carcinoma.